There are currently 455 clinical trials in Little Rock, Arkansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arkansas for Medical Sciences, Arkansas Children's Hospital, GSK Investigational Site and Arkansas Cancer Research Center at University of Arkansas for Medical Sciences. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
Recruiting
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 80 mg BID orally or matching placebo BID in each of two treatment periods.
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
03/11/2025
Locations: Clinical Trials, Inc. (CTI), Little Rock, Arkansas
Conditions: Epilepsy, Generalized, Epilepsy, Absence
Nutritional Therapy for Delirium in Elderly Hospitalized Subjects
Recruiting
The investigators have developed a proprietary blend of amino acids that they think will help to prevent or reduce the severity of delirium in older adults (60 years and older) who are hospitalized for certain infections. In this study, up to 45 people will be enrolled.15 will be asked to drink this blend twice a day for up to 4 days, and 15 will receive standard treatment in the hospital for the same time period. The other 15 subjects will be non-delirious control subjects who do not consume an... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/10/2025
Locations: UAMS Center on Aging, Little Rock, Arkansas
Conditions: Subacute Delirium
A PIVOTAL STUDY EVALUATING SAFETY and EFFICACY of the SHIRATRONICS MIGRAINE THERAPY SYSTEM
Recruiting
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/04/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Headache Migraine Chronic
Study of LAM561 Acid in Pediatric Patients with Malignant Glioma and Other Advanced Solid Tumors
Recruiting
An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3" design to establish dose-limiting toxicity (DLT) and a "safe" dose of LAM561 followed by an expanded safety cohort of up to 10 patients treated at the Maximum Tolerated Dose (MTD). If the MTD is well tolerated in the expanded safety cohort, that dose becomes the Recomm... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/03/2025
Locations: Arkansas Children's Research Institute, Little Rock, Arkansas
Conditions: High-grade Glioma, Solid Tumor, Unspecified, Child
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Arkansas for Medical Sciences /ID# 243096, Little Rock, Arkansas
Conditions: Relapsed/Refractory Multiple Myeloma
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Recruiting
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Recruiting
To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
02/27/2025
Locations: Vanda Investigational Site, Little Rock, Arkansas
Conditions: Schizophrenia, Bipolar I Disorder
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Recruiting
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: University of Arkansas Medical Center, Little Rock, Arkansas
Conditions: Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
Amplatzer Amulet LAAO Vs. NOAC
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: UAMS Medical Center, Little Rock, Arkansas
Conditions: Atrial Fibrillation, Stroke, Bleeding
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
Recruiting
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/25/2025
Locations: Neurocrine Clinical Site, Little Rock, Arkansas
Conditions: Major Depressive Disorder
In Vivo Detection of Circulating Clots in Patients With Thromboembolism
Recruiting
Subjects with thromboembolic disease or at high-risk for thromboembolic conditions diagnosed with ultrasound or other standard of care techniques will be recruited to estimate the feasibility of a device to detect in vivo CBCs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Univerisity of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Thromboembolism
Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
Recruiting
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo. * To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo Participants will attend the foll... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Applied Research Center of Arkansas, Little Rock, Arkansas
Conditions: Irritable Bowel Syndrome With Diarrhea